Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2012

View Archived Issues

Phase II ALS trial set to begin with fingolimod

Self-propelled microrockets with drug delivery potential function in acidic environments

Exelixis synthesizes lysophospholipid S1P1 receptor antagonists with antitumor potential

China Medical University presents new sodium/iodide cotransporter proteins

Nippon Chemiphar patents novel P2X4 receptor antagonists

Russian team patents novel interferon alfa-2b conjugates

Japanese researchers present new protein kinase inhibitors

Dako and Amgen begin new collaboration

CHMP issues opinion on Humira in ulcerative colitis

Fuso Pharmaceutical synthesizes new agents to treat cancer

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized by Sanofi

EMA adopts scientific opinion on Pyramax

Pivotal Takeda trial meets primary endpoints

Studies clarify genetic basis of Bartsocas-Papas syndrome

Critical Pharma and U.K. university team up to develop nasal spray for osteoporosis

FDA accepts Actemra sBLA for review

Genticel completes recruitment in phase Ib trial of HPV vaccine

Redevant launched in Mexico

GSK exercises exclusive license option for compounds developed with Galapagos

CHMP requests additional information on Glybera

Amsterdam Molecular Therapeutics' assets and liabilities to be acquired by uniQure

Threshold Pharmaceuticals' phase IIb study in pancreatic cancer meets primary endpoint

Novel inhibitor of V600-mutant B-raf shows antitumor activity in animal models

UMN Pharma licenses novel norovirus and rotavirus combination vaccine candidate

FDA places clinical hold on Capesaris

Innocoll announces successful end-of-phase II meeting with FDA for XaraColl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...